Department of Dermatology and Allergy, Hannover Medical School, Skin Cancer Center Hannover, Hannover, Germany.
Dermatology. 2013;227(4):289-94. doi: 10.1159/000355181. Epub 2013 Nov 7.
In advanced cutaneous squamous cell carcinoma (cSCC), efficient medical treatment options are limited in case surgery and radiotherapy failed, particularly since most patients are of higher age and suffer from comorbidities. In many tumor entities, the epidermal growth factor receptor (EGFR) has been established as an important therapeutic target, and blockade of EGFR signaling by monoclonal antibodies or small molecules achieves a therapeutic benefit. EGFR expression is also often dysregulated in cSCC. We report here two patients with advanced cSCC treated with the EGFR inhibitor cetuximab and summarize the current published experience with the use of EGFR inhibitors in cSCC.
在晚期皮肤鳞状细胞癌（cSCC）中，如果手术和放疗失败，有效的治疗选择有限，特别是因为大多数患者年龄较大且患有合并症。在许多肿瘤实体中，表皮生长因子受体（EGFR）已被确立为重要的治疗靶点，通过单克隆抗体或小分子阻断 EGFR 信号传导可实现治疗获益。cSCC 中也经常出现 EGFR 表达失调。我们在此报告两例接受 EGFR 抑制剂西妥昔单抗治疗的晚期 cSCC 患者，并总结目前 EGFR 抑制剂在 cSCC 中的应用经验。
